T-cell receptor beta variable domain (TRBV)

The T-cell receptor beta variable (TRBV) domain is the highly polymorphic region of the T-cell receptor (TCR) responsible for recognizing specific peptide antigens presented by the Major Histocompatibility Complex (MHC) (UniProt, 2024). In humans, there are approximately 30 functional TRBV families, and each individual T cell expresses only one specific Vβ family due to allelic exclusion. This biological property is particularly relevant in T-cell malignancies, such as peripheral T-cell lymphomas, where the entire tumor population is derived from a single clone and thus expresses a unique TRBV domain (Maciocia et al., 2017). By targeting the specific Vβ family associated with the malignant clone, therapeutic agents like monoclonal antibodies or CAR-T cells can selectively eliminate cancer cells while leaving the majority of the healthy T-cell compartment intact. This approach offers a precision medicine strategy that minimizes the severe, global immunosuppression typically seen with pan-T-cell therapies like anti-CD3 or anti-CD52. Beyond oncology, targeting pathogenic Vβ families is also being explored as a method to treat autoimmune diseases driven by restricted, autoreactive T-cell populations (U.S. National Library of Medicine, 2024).

Other names

TCR V-betaT-cell receptor VβTRBV domainT-cell receptor beta chain variable regionT-cell receptor beta variable

Selective depletion of specific T-cell clones expressing a particular Vβ family through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or CAR-T mediated lysis, thereby eliminating malignant or pathogenic cells while preserving the rest of the T-cell repertoire (Maciocia et al., 2017; U.S. National Library of Medicine, 2024).